Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages
Dopamine agonists are safe and only required treatment in 2/3 of patients treated with pharmacotherapy as a first-line treatment. Higher doses of cabergoline accelerate prolactin normalisation but do not confer additional benefit in early tumour shrinkage.
Authors
- Luís San Román (ORCID: https://orcid.org/0000-0003-0735-4373)
- David Netuka (ORCID: https://orcid.org/0000-0001-8609-4789)
- Dietrich Pavel
- Martin Májovský (ORCID: https://orcid.org/0000-0001-7725-5181)
- Václav Hána
- J Jana
- Kowara Michał
- Vaněčková Manuela
- Krausová Adéla
- Kosák Mikuláš
- Masopust Václav
Institutions
- Charles University (CZ)
- Na Homolce Hospital (CZ)
- Military University Hospital Prague (CZ)
- General University Hospital in Prague (CZ)
Publication Details
- Journal
- Journal of Clinical & Translational Endocrinology
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1016/j.jcte.2025.100418
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00